Ionis Pharmaceuticals (IONS) announced that it is floating a secondary issue of 11.5 million shares of its common stock to the public at an issue price of $43.50 per share, amounting to nearly $500.3 million. The company also granted an option to underwriters of the issue to purchase an additional 1.725 million shares at the same price. The secondary offering is expected to close today. Buy Why Did IONS Stock Fall? Ionis' shares fell more than 12% on Tuesday after the announcement. Though the issue does not ...

CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The shares of common stock are being sold at a public offering price of $43.50 per share. The aggregate gross proceeds to Ionis from this offering are expected to be approximately $500.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ionis. Ionis ha ...

CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock offered in the public offering on the same terms and conditions. Ionis intends to use the net proceeds from the offering to fund its independent commercial launches, late-stage clinical programs ...

California-based Ionis Pharmaceuticals (IONS) is focused on the discovery and development of RNA-targeted therapies using its proprietary platform for itself and its partners. It uses this technology to generate a broad pipeline of medicines, targeting neurological, cardiovascular and specialty rare diseases. Despite marketing no wholly-owned drug in its portfolio, IONS enjoys a diverse stream of revenues, including commercial products and royalties and numerous sources of collaborative and R&D revenues. Th ...

kemalbas Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a biopharmaceutical company specializing in RNA-targeted therapies. It uses antisense DNA technology to design drugs that regulate the production of specific proteins to treat neurological and cardiometabolic diseases, directly addressing their root causes. The company presents an extensive pipeline with partnered and in-house drug developments to address several conditions. It also collaborates with major pharmaceutical companies like Biogen (BIIB), Ast ...

Ionis Pharmaceuticals (IONS) incurred a loss of 45 cents per share for second-quarter 2024, which was narrower than the Zacks Consensus Estimate of a loss of 95 cents per share. Earnings include compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 24 cents against a loss of 40 cents per share in the year-ago quarter. Total revenues were $225 million in the second quarter, which beat the Zacks Consensus Estimate of $147.0 million. Revenues rose 20% year o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading symbol Name of each exchange on which registered Common Stock, $.001 Par Value "IONS" The Nasdaq Stock Market LLC Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commissi ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2024 Earnings Conference Call August 1, 2024 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Richard Geary - Executive Vice President and Chief Development Officer Kyle Jenne - Executive Vice President and Chief Global Product Strategy Officer Elizabeth Hougen - Executive Vice President and Chief Financial Officer Eric Swayze - Executive Vice President of Research Eugene Schneider - E ...

Exhibit 99.1 Ionis reports second quarter 2024 financial results WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., August 1, 2024 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the second quarter of 2024. "Over the fir ...

For the quarter ended June 2024, Ionis Pharmaceuticals (IONS) reported revenue of $225 million, up 19.7% over the same period last year. EPS came in at -$0.45, compared to -$0.60 in the year-ago quarter. The reported revenue represents a surprise of +52.56% over the Zacks Consensus Estimate of $147.49 million. With the consensus EPS estimate being -$0.95, the EPS surprise was +52.63%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...